RegeneRx’s highest priority is the development of RGN-259, a Tβ4-based sterile and preservative-free eye drop, as a novel treatment for dry eye disease and neurotrophic keratitis (NK), a persistent corneal defect caused by diabetes and …

RegeneRx drug candidate, RGN-259, is the subject of five Phase 3 clinical trials in the U.S., and EU for patients with dry eye disease (DED) and neurotrophic keratitis (NK, an orphan indication).

Apr 13, 2023 · RGN-259, whose active ingredient is thymosin beta 4 (Tβ4), is a novel drug candidate that promotes cell migration, anti-inflammation, and wound healing. RGN-259 is formulated as a...

Jul 12, 2018 · In this study, we investigated the effects of RGN-259 topical treatment on the cornea, conjunctiva, and lacrimal glands in a murine dry eye model, and we also compared the effects of...

Jan 3, 2023 · RGN-259 is a sterile, preservative-free, eye drop developed to reduce damage and improve healing for various ophthalmic indications including dry eye syndrome and neurotrophic keratopathy. To date, over 1700 subjects have received RGN-259 indicating various degrees of efficacy in both DED and NK.

May 20, 2015 · Background: The purpose of this study was to evaluate the safety and efficacy of thymosin beta 4 ophthalmic solution (RGN-259; Tβ4) in subjects with moderate to severe dry eye using the CAE™ model.

RGN-259, or thymosin beta 4, is a ubiquitous low molecular weight protein that promotes cell migration and wound healing and has anti-inflammatory properties. This phase 2b/3 clinical study evaluated the safety and efficacy of RGN-259 for the treatment of dry eye.

Jan 3, 2023 · RGN-259 is a sterile, preservative-free, eye drop developed to reduce damage and improve healing for various ophthalmic indications including dry eye syndrome and neurotrophic...

Dec 29, 2022 · We determined the efficacy and safety of 0.1% RGN-259 ophthalmic solution (containing the regenerative protein thymosin ß4) in promoting the healing of persistent epithelial defects in patients with Stages 2 and 3 neurotrophic keratopathy.

Oct 29, 2021 · ReGenTree has been developing a new ophthalmic eye drop for NK treatment using Thymosin Beta 4 (Tβ4), the active pharmaceutical ingredient of RGN-259, the drug candidate under development.